These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32981311)

  • 21. A single approach to targeting transferrin receptor 2 corrects iron and erythropoietic defects in murine models of anemia of inflammation and chronic kidney disease.
    Olivari V; Di Modica SM; Lidonnici MR; Aghajan M; Cordero-Sanchez C; Tanzi E; Pettinato M; Pagani A; Tiboni F; Silvestri L; Guo S; Ferrari G; Nai A
    Kidney Int; 2023 Jul; 104(1):61-73. PubMed ID: 36990212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease.
    Nakanishi T; Kimura T; Kuragano T
    Contrib Nephrol; 2019; 198():124-134. PubMed ID: 30991414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model.
    Garrido P; Ribeiro S; Fernandes J; Vala H; Bronze-da-Rocha E; Rocha-Pereira P; Belo L; Costa E; Santos-Silva A; Reis F
    PLoS One; 2015; 10(4):e0124048. PubMed ID: 25867633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
    Sugahara M; Tanaka T; Nangaku M
    Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors.
    Packer M
    Eur Heart J; 2023 Dec; 44(48):5027-5035. PubMed ID: 37086098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enarodustat to treat anemia in chronic kidney disease.
    Fukui K; Tanaka T; Nangaku M
    Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype.
    Imeri F; Nolan KA; Bapst AM; Santambrogio S; Abreu-Rodríguez I; Spielmann P; Pfundstein S; Libertini S; Crowther L; Orlando IMC; Dahl SL; Keodara A; Kuo W; Kurtcuoglu V; Scholz CC; Qi W; Hummler E; Hoogewijs D; Wenger RH
    Kidney Int; 2019 Feb; 95(2):375-387. PubMed ID: 30502050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond.
    Ueda N; Takasawa K
    Curr Med Chem; 2017; 24(14):1417-1452. PubMed ID: 28302014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron suppresses erythropoietin expression via oxidative stress-dependent hypoxia-inducible factor-2 alpha inactivation.
    Oshima K; Ikeda Y; Horinouchi Y; Watanabe H; Hamano H; Kihira Y; Kishi S; Izawa-Ishizawa Y; Miyamoto L; Hirayama T; Nagasawa H; Ishizawa K; Tsuchiya K; Tamaki T
    Lab Invest; 2017 May; 97(5):555-566. PubMed ID: 28263291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
    Nangaku M
    Rinsho Ketsueki; 2021; 62(8):938-943. PubMed ID: 34497234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrogen Sulfide Induced Erythropoietin Synthesis is Regulated by HIF Proteins.
    Leigh J; Saha MN; Mok A; Champsi O; Wang R; Lobb I; Sener A
    J Urol; 2016 Jul; 196(1):251-60. PubMed ID: 26880412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
    Jain M; Joharapurkar A; Patel V; Kshirsagar S; Sutariya B; Patel M; Patel H; Patel PR
    Eur J Pharmacol; 2019 Jan; 843():113-120. PubMed ID: 30458168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
    Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease.
    Hamano H; Ikeda Y; Watanabe H; Horinouchi Y; Izawa-Ishizawa Y; Imanishi M; Zamami Y; Takechi K; Miyamoto L; Ishizawa K; Tsuchiya K; Tamaki T
    Nephrol Dial Transplant; 2018 Apr; 33(4):586-597. PubMed ID: 28992067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model.
    Hanudel MR; Rappaport M; Gabayan V; Jung G; Salusky IB; Nemeth E; Ganz T; Zaritsky J
    Haematologica; 2017 Mar; 102(3):e85-e88. PubMed ID: 27884972
    [No Abstract]   [Full Text] [Related]  

  • 39. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
    Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
    J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
    Sheetz M; Barrington P; Callies S; Berg PH; McColm J; Marbury T; Decker B; Dyas GL; Truhlar SME; Benschop R; Leung D; Berg J; Witcher DR
    Br J Clin Pharmacol; 2019 May; 85(5):935-948. PubMed ID: 30677788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.